According to the findings of the SOLAR I trial, tumors with PIK3CA mutations benefit from Alpelisib in conjunction with Fulvestrant, making this a treatment option for patients with ER-positive (ER+)/HER2-negative advanced BC. This evidence concerns the gene ERBB2 and breast cancer.